Advertisement

Topics

FDA Grants Orphan Drug Designation to Ocugen’s OCU300 for Ocular Graft Versus Host Disease

09:18 EDT 9 Aug 2017 | Speciality Pharma Journal

MALVERN, Pa., Aug. 9, 2017 /PRNewswire/ — Ocugen, Inc., a clinical stage biopharmaceutical company developing novel treatments for sight-threatening diseases, today announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for OCU300 (brimonidine tartrate) for the treatment of ocular graft versus host disease (oGVHD). Ocular GVHD is a common complication …

Original Article: FDA Grants Orphan Drug Designation to Ocugen’s OCU300 for Ocular Graft Versus Host Disease

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Orphan Drug Designation to Ocugen’s OCU300 for Ocular Graft Versus Host Disease"

Quick Search
Advertisement
 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...